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Epibatidine is an alkaloid toxin that binds with high afﬁnity to nicotinic and muscarinic acetylcholine
receptors, and has been extensively used as a research tool. To examine binding interactions at the
nicotinic receptor, it has been co-crystallised with the structural homologue acetylcholine binding
protein (AChBP; PDB ID 2BYQ), and with an AChBP chimaera (3SQ6) that shares 64% sequence identity
with the a7 nACh receptor. However, the binding orientations revealed by AChBP co-crystal structures
may not precisely represent their receptor homologues and experimental evidence is needed to verify
the ligand poses. Here we identify potential binding site interactions between epibatidine and AChBP
residues, and substitute equivalent positions in the a7 nACh receptor. The effects of these are probed by
[3H]epibatidine binding following the expression a7 nACh receptor cysteine mutants in HEK 293 cells. Of
the sixteen mutants created, the afﬁnity of epibatidine was unaffected by the substitutions Q55C, L106C,
L116C, T146C, D160C and S162C, reduced by C186A and C187A, increased by Q114C and S144C, and
abolished by W53C, Y91C, N104C, W145C, Y184C and Y191C. These results are consistent with the
predicted orientations in AChBP and suggest that epibatidine is likely to occupy a similar location at a7
nACh receptors. We speculate that steric constraints placed upon the C-5 position of the pyridine ring in
3SQ6 may account for the relatively poor afﬁnities of epibatidine derivatives that are substituted at this
position.
Crown Copyright © 2017 Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
a7 nACh receptors are considered to be valuable drug targets as
they modulate many physiological responses and are associated
with neurological disorders and pathological conditions such as
Alzheimer's, Parkinson's and schizophrenia (Hernandez and
Dineley, 2012; Mazurov et al., 2011; Thomsen et al., 2010). Conse-
quently there have been continued efforts to develop new ligands
that target these receptors, both as drug candidates and as phar-
macological research tools. Knowledge of how the ligands orientateCh, nicotinic acetylcholine;
yonic kidney; AChBP, acetyl-
iﬁed to resemble the 5-HT3R
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evier Ltd. This is an open access ain the receptor binding site can provide insights into where mod-
iﬁcations might be tolerated. Such changes can be used to improve
their pharmacological properties and aid the coupling of functional
groups such as ﬂuorescent labels, thiol-reactive moieties and
photo-afﬁnity probes (Lochner and Thompson, 2015).
a7 nACh receptors belong to the Cys-loop family of trans-
membrane ligand-gated ion-channels that are responsible for fast
synaptic neurotransmission in the central and peripheral nervous
systems. All members of this family are composed of ﬁve subunits,
each of which contains an extracellular, a transmembrane and an
intracellular domain (Thompson et al., 2010; Unwin, 2005).
Competitive ligands such as acetylcholine or epibatidine bind at an
extracellular, orthosteric binding site that is located at the interface
of two adjacent subunits (Fig. 1). This site is a hydrophobic cavity
created by the convergence of loops A e C from the principal
subunit and loops D e F from the complementary subunit (Fig. 1).
However, owing to the difﬁculty of crystallising membrane pro-
teins, a soluble structural homologue (acetylcholine binding pro-
tein; AChBP), has been commonly used to study the binding
orientations of a7 nACh receptor ligands. Examples include therticle under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Fig. 1. Locations of residues mutated in this study. A. A cartoon showing the binding site of AChBP with binding loops A e F highlighted in colour. The binding site is found at the
interface of two adjacent subunits, and for clarity only two of the ﬁve subunits of the native receptor are shown. The structure is 3SQ6, but the location of the membrane has been
indicated to show where it would be located in the a7 nACh receptor. B. An amino acid sequence alignment of the a7 nACh receptor and sequences from the two crystal structures
(2BYQ & 3SQ6) in which epibatidine has been co-crystallised. The binding loops are shown in the same colours as in panel A, and amino acids that are within 5 Å of epibatidine are
highlighted as white text in grey boxes on the AChBP structures. The equivalent a7 nACh residues substituted in this study are shown as white text in black boxes. a7m5HT3 ¼ chick
a7nACh chimaera; 3SQ6 ¼ Ls-AChBP-a7 nACh chimaera; 2BYQ ¼ Ac-AChBP. The residue numbering used in this manuscript corresponds to residues in the crystal structure 3SQ6.
2BYQ and 3SQ6 share 31.8% identity and 49.8% similarity in their sequences (EMBOSS Needle; Rice et al., 2000). C. The structure and atom numbering of protonated epibatidine is
shown below the alignment.
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A.J. Thompson et al. / Neuropharmacology 116 (2017) 421e428 423agonists acetylcholine (3WIP), anabasine (2WNL), carbamylcholine
(1UV6), cytisine (4BQT), epibatidine (2BYQ, 3SQ6), nicotine
(1UW6), tropisetron (2WNC) and varenicline (4AFT, 4AFG), and
antagonists such as lobeline (2BYS, 4AFH, 5AFH) and methyl-
lycaconitine (2BYR). Owing to the relatively high sequence simi-
larity of AChBP and the a7 nACh receptor (64%) it is generally
thought that the orientations of ligands in the crystals will be
similar to those in the a7 nACh receptor. Consequently these
structures have been used to direct efforts in the chemical synthesis
of novel ligands and for computational methods such as molecular
dynamic simulations (Akdemir et al., 2012; Camacho-Bustamante
et al., 2016; Yamauchi et al., 2012). While several studies report
the successful creation of novel a7 nACh receptor ligands, AChBP
co-crystal structures should still be viewed with caution as some of
the ligands they contain also bind to other Cys-loop family mem-
bers where they have different afﬁnities and functional effects. For
example, varenicline inhibits nACh receptors, but is a partial
agonist of 5-HT3 receptors (Lummis et al., 2011). Similarly, tropi-
setron is a partial agonist of a7 nACh receptors and a higheafﬁnity
antagonist of 5-HT3 and glycine receptors (Macor et al., 2001; Yang
et al., 2007). Such dramatic pharmacological differences suggest
that some ligands may have distinct orientations at the different
Cys-loop receptors and that the AChBP structures are not always
representative of all family members.
Here we probe residues that lie within 5 Å of bound epibatidine
in the AChBP crystal structures 2BYQ and 3SQ6, and residues
identiﬁed by in silico docking into AChBP homology models. By
substituting the equivalent residues at a7 nACh receptors we
determine whether their effects on [3H]epibatidine binding are
consistent with the ligand orientations predicted from the
structures.2. Materials and methods
2.1. Computational analysis
To gain insights into potential binding-site interactions, residues
located within 5 Å of epibatidine were identiﬁed from two AChBP
crystals structures (2BYQ & 3SQ6). Additionally, in silico ligand
docking was performed on epibatidine docked into AChBP crystal
structures bound with the a7 nACh receptor agonists acetylcholine
(3WIP), anabasine (2WNL), carbamylcholine (1UV6), cytisine
(4BQT), nicotine (1UW6), tropisetron (2WNC) and varenicline
(4AFT). Agonist-bound structures were chosen as these are likely to
havemore appropriate binding site conformations than antagonist-
bound structures; the conformational changes induced by agonist
binding can have dramatic effects on ligand binding (Colquhoun,
1998). The calculated pKa value of the bicyclic amine of epi-
batidine (Fig. 1) was 10.5 using MarvinSketch v15.3 and therefore
the protonated and three-dimensional structure of epibatidine was
constructed ab initio using Chem3D Pro v14.0 (CambridgeSoft,
Cambridge, UK). The generated ligand was subsequently energy-
minimised using the implemented MM2 force ﬁeld. The binding
site in AChBPwas deﬁned as beingwithin 10 Å of the centroid of the
aromatic side-chain of W145, a residue that is centrally located in
the binding site and known to be important for the binding of
competitive ligands (Thompson et al., 2010). Epibatidine was
docked using GOLD Suite v5.3 (The Cambridge Crystallographic
Data Centre, Cambridge, UK) with the GoldScore function and
default settings. For each AChBP template, ten docking poses were
generated. All residues within 5 Å of epibatidine were identiﬁed in
each of docked poses and these residues and their potential in-
teractions visualised using PyMol v1.3 (Schr€ondinger, NY, USA).2.2. Receptors
Mutagenesis was performed using the QuikChange method
(Agilent Technologies Inc., CA, USA) to substitute amino acids
throughout each of the binding loops A e F (Fig. 1). The a7 nACh-5-
HT3 subunit cDNAwas as described by Bertrand (Eisele et al., 1993)
and was cloned into pcDNA3.1 for expression in HEK293 cells.
Human 5-HT3A cDNA (accession number: P46098) and mouse 5-
HT3A cDNA (Q6J1J7) were cloned into the same vector. Cells were
transiently transfected with this cDNA using either poly-
ethyleneimine (PEI: 25 kDa, linear, powder, Polysciences Inc.,
Eppelheim, Germany) or Lipofectamine 2000 (Life Technologies,
CA, USA) according to the manufacturer's instructions. 30 ml of PEI
(1 mg ml1), 5 mg cDNA and 1 ml DMEM/F12 were incubated for
10 min at room temperature, added drop wise to a 90 mm plate of
70e80% conﬂuent HEK293 cells, and incubated for 2e3 days before
use.
2.3. Cell culture and transfection
Human embryonic kidney (HEK) 293 cells were grown on
90 mm round tissue culture plates as monolayers in DMEM/F12
(Life Technologies) supplemented with 10% fetal bovine serum
(FBS; Sigma Aldrich) at 37 C in a moist atmosphere containing 5%
CO2.
2.4. Radioligand binding
Transfected HEK 293 cells were scraped into 0.6 ml of ice-cold
10 mM HEPES buffer (pH 7.4) and stored frozen. After thawing,
they were washed with HEPES buffer, homogenised by passage
through a 21 G needle, and 50 mg of cell suspension incubated in
0.5 ml HEPES buffer containing [3H]epibatidine (55.8 Ci/mmol,
Waltham, MA). Non-speciﬁc binding was determined using 300 mM
()-nicotine. Equilibrium reactions were incubated on ice for at
least 1 h. Incubations were terminated by vacuum ﬁltration onto
Whatman GF/B ﬁlters wetted with 0.3% polyethyleneimine, fol-
lowed by two rapid washes with 2.5 ml ice cold buffer. Radioac-
tivity was determined by scintillation in Ultima Gold XR (Perkin
Elmer) using a Tri-Carb 2100 TR (PerkinElmer) scintillation counter.
Final counts weremonitored to ensure that binding never exceeded
10% of the added concentrations of radioligands.
2.5. Data analysis
All data were analysed using GraphPad Prism v5. Individual
saturation binding experiments were ﬁtted to Eq. (1):
y ¼ Bmax  ½L KdKd þ ½L
(1)
where Bmax is maximum binding at equilibrium, Kd is the equilib-
rium dissociation constant and [L] is the free concentration of
radioligand. Values from individual experiments were averaged to
yield the mean ± sem. Afﬁnities were compared using 1-way
ANOVA and a Dunnett's Post-Test.
2.6. Detection
48 h post transfection, HEK293 cells were harvested in 10 ml
phosphate buffered saline (137 mM NaCl, 10 mM Na2HPO4, 2.7 mM
KCl, 2 mM KH2PO4, pH 7.4), centrifuged 5 min at 220 g and the
pellets stored at 80 C. Total extracts were prepared by resus-
pension of 1  107 cells in 1 ml lysis buffer (10 mM Tris-HCl pH 7.5,
10 mM NaCl, 2 mM EDTA, 5 mMMnSO4, 4 Halt Protease Inhibitor
A.J. Thompson et al. / Neuropharmacology 116 (2017) 421e428424(Thermo Fisher Scientiﬁc), 0.2 mg ml1 RNase A (Sigma-Aldrich),
500 U ml1 Cyanase (RiboSolutions, TX, USA), 0.1% Triton X-100)
followed by 30 min on ice. Extracts were supplemented with
NuPage LDS buffer (Thermo Fischer Scientiﬁc) and heated at 70 C
for 10 min. 105 cell equivalents were loaded on a 4e12% Bis-Tris
NuPage gel and blotted on nitrocellulose using the iBlot system
(ThermoFisher Scientiﬁc). a7 nACh-5-HT3 chimaeras were detected
with 1:250 rabbit polyclonal antibody (ASR-031; Alomone Labs,
Jerusalem, Isreal) and 1:10000 goat anti-rabbit IRDye800CW (926-
32211; LI-COR Biosciences, NE, USA). CPSF-100 served as a loading
control and was detected using 1:10000 rabbit polyclonal antibody
(kindly provided by Georges Martin & Walter Keller, University of
Basel) and 1:10000 goat anti-Rabbit IRDye680LT (925-68021, LI-
COR Biosciences). Signals were improved using SuperSignal West-
ern Blot Enhancer (Thermo Fischer Scientiﬁc) according to the
manufacturer's instructions.Fig. 2. Example binding curves for [3H]epibatidine at wild type and mutant a7 nACh
receptors.3. Results & discussion
[3H]epibatidine displayed high-afﬁnity saturable binding at a7
nACh receptors with a Kd (8 nM) similar to that reported elsewhere
(Li et al., 2011; Xiao et al., 2012). To better understand the residues
that govern this binding interaction, elsewhere crystal structures of
homologous AChBP have been used as substitutes for this receptor
(Hansen et al., 2005; Li et al., 2011). Here we examined whether
these co-crystal structures are good representations of epibatidine
binding at a7 nACh receptors and used them to speculate why
chemical modiﬁcation of this ligandmay have previously generated
much lower afﬁnity ﬂuorescent derivatives (Grandl et al., 2007). To
this end we identiﬁed potential ligand-receptor interactions by
examining the orientations of epibatidine in AChBP crystal struc-
tures and following in silico docking into other agonist-bound
AChBP structures. Using radioligand binding we determined
whether these interactions are consistent with the effects of
substituting equivalent residues in the a7 nACh receptor.
Residues within 5 Å of epibatidine were identiﬁed in the co-
crystal structures 2BYQ and 3SQ6, and following in silico docking
into seven other agonist-bound AChBP templates; acetylcholine
(3WIP), anabasine (2WNL), carbamylcholine (1UV6), cytisine
(4BQT), nicotine (1UW6), tropisetron (2WNC) and varenicline
(4AFT). For each template 10 docked poses were generated, yielding
a total of 72 independent ligand orientations when both these and
the crystal structures are considered (Table 1). However, when all
poses were compared there was very little difference between
orientations of epibatidine (RMSD ¼ 0.78 Å average), suggesting
that its orientation is tightly conﬁned by the agonist-bound
conformation. For each of the main residues identiﬁed in theseTable 1
Summary of all residues lying within 5 Å of epibatidine.
Principal Face C
PDB id A B C
3SQ6
Y
91
S1
44
W
14
5
T1
46
Y
18
4
C
18
6
C
18
7
Y
19
1
2BYQ Y T S W T Y C C Y
1UV6 Y S W T Y C C Y
1UW6 Y S W T Y C C Y
3WIP Y S W T Y C C Y
4AFT Y S W V Y C C Y
2WNC Y S W V Y C C Y
2WNL Y S W V Y C C Y
4BQT Y S W V Y C C Y
Locations of the most predominant residues can be found in Figs. 1 and 4. Only the numb
structures of epibatidine bound to AChBP. Epibatidine has been docked into the remainiposes, Cys substitution at the equivalent residue positions in the a7
nACh receptor was undertaken and the binding afﬁnity of [3H]
epibatidine at these mutants was measured (Fig. 2, Table 2).
Changing 6 of the 16 residues resulted in no signiﬁcant change inomplementary Face
D E F
W
53
L1
04
A
10
5
L1
06
Q
11
4
Y
11
5
L1
16
Y I A V M F I
W L A R L Y M
W L A R L Y M
W L A R L Y M
Y R I A V M F I
Q Y I A V M F I S
Y I A V M F I
Y R I A V M F I P
ering for 3SQ6 has been included to avoid confusion. 3SQ6 and 2BYQ are co-crystal
ng structures shown. A e F ¼ binding loops (see Fig. 1).
Table 2
Saturation binding of [3H]epibatidine at mutant a7 nACh receptors.
Fig. 3. Expression of mutant a7nACh receptors. Several mutant receptors did not bind
[3H]epibatidine. To conﬁrm that this was a change in the binding afﬁnity rather than
altered expression, these mutants were probed by Western blot using a receptor-
speciﬁc antibody directed against the 5-HT3 region of the chimaeric receptor.
Expression levels of the mutants and wild type receptors were comparable (black
arrow), and there was no detection in untransfected cells. In each lane 105 cell
equivalents were loaded. The membrane was cut at 70 kDa and the upper section was
incubated with an antibody of cleavage and polyadenylation speciﬁcity factor (CPSF) to
provide an internal control. For both Western blots and radioligand binding the same
whole-cell homogenates were used, ensuring that the same population of receptors
was probed.
A.J. Thompson et al. / Neuropharmacology 116 (2017) 421e428 425afﬁnity when compared to wild type a7 nACh receptors (Q55, L106,
L116, T146, D160, S162), suggesting these residues do not play a
signiﬁcant role in ligand binding or the conformation of the binding
site. For the remaining 10 mutants there were differences in the
binding afﬁnities. Of these, 2 had increased afﬁnities (Q114C,
S144C), 2 had decreased afﬁnities (C186A, C187A) and 6 showed no
saturable binding (Kd > 20 nM;W53C, Y91C, N104C,W145C, Y184C,
Y191C). For mutants that did not show saturable binding, Western
blots were performed to conﬁrm receptor expression (Fig. 3). The
observed signals showed that all mutants were expressed and the
absence of measurable binding could be attributed to changes in
binding site interactions, or to altered gating which can also impact
the afﬁnity (Colquhoun, 1998).
In the principal binding interface of the a7 nACh receptor, Cys
substitution of Y91 in loop A abolished binding, indicating a key
interaction. In the AChBP co-crystal structure 3SQ6, Y91 forms a
cation-p interaction with K141 and a hydrogen bond with epi-
batidine (Fig. 5A), both of which have also been observed in func-
tional assays on a7 nACh receptors. For example, removing the
hydrogen bonding capability of Y91 by substitution with Phe
caused a dramatic reduction in the afﬁnity of a7 nACh for epi-
batidine, while unnatural amino acid mutagenesis identiﬁed a
cation-p interaction at the same location (Li et al., 2011; Puskar
et al., 2011). In loop B, Cys substitution of the aromatic residue
W145 also abolished epibatidine binding, indicating another
important effect. This centrally located aromatic residue is highly
Fig. 4. Binding site residues mutated in this study, highlighted on the AChBP receptor
crystal structure 3SQ6 and colour coded by whether substitution caused no change in
the afﬁnity for epibatidine (green), decreased afﬁnity (red), or increased afﬁnity (blue).
The afﬁnities of each mutant and the fold-change relative to the wild-type receptor can
be found in Table 2. EPI ¼ epibatidine. (For interpretation of the references to colour in
this ﬁgure legend, the reader is referred to the web version of this article.)
A.J. Thompson et al. / Neuropharmacology 116 (2017) 421e428426conserved across the Cys-loop family and even conservative sub-
stitutions at this location can impact ligand binding (Li et al., 2011;
Puskar et al., 2011; Thompson et al., 2010; Van Arnam et al., 2013;
Williams et al., 2009). In both of the AChBP crystal structures this
residue is seen to form a cation-p interaction with epibatidine, but
unnatural amino acid mutagenesis of a7 nACh receptors suggests
that such an interaction is not present (Puskar et al., 2011). For other
ligands an interaction at this location is not always essential for
agonist function at a7 nACh receptors, as shown by mutations to
Ala and Gly that cause only small changes in the function of ACh
and no change for the compound 4OH-GTS-2 (Williams et al.,
2009). In contrast, our results suggest that W145 has a more
important role for epibatidine, and are consistent with ﬁndings that
even a conservative W145F mutation at a7 nACh receptors reduces
the afﬁnity of epibatidine by > 2200-fold (Li et al., 2011). At other
residue positions in Loop B the effects of mutation were not as
pronounced. For example, S144 and T146 lay either side of W145,
and although mutation of these residues can have quite dramatic
effects for ligands acting at other Cys-loop receptors, it had little or
no effect on epibatidine (Thompson et al., 2010). Based on crystal
structure evidence, both of these residues contribute to a network
of hydrogen bonds, and it is therefore possible that the ability of the
thiol side chain of Cys (which can also act as a weak hydrogen bond
donor) might preserve this property. Elsewhere mutation of other
loop B residues K141 and G149 had only minor effects on the EC50
or the binding afﬁnity of epibatidine at a7 nACh receptors and as
both are located distant (>6.5 Å) from the bound ligand in AChBP
our results are also consistent with these previous ﬁndings (Criado
et al., 2005; Grutter et al., 2003). In loop C, no epibatidine binding
was detected following the substitution Y191C. Consistent with this
result, mutation of Y191 to Phe decreases its afﬁnity and unnatural
amino acid mutagenesis has provided evidence that Y191 forms a
cation-p interactionwith epibatidine at a7 nACh receptors (Li et al.,
2011; Puskar et al., 2011). In AChBP the closely located residues
Y184, C186 and C187 make extensive van der Waals contacts withepibatidine via its azabicyclo moiety (Hansen et al., 2005; Li et al.,
2011). In our study of a7 nACh receptors, epibatidine binding was
not detectable following Y184C substitution, a ﬁnding that is
comparable to the >250-fold change that was previously reported
following the modest substitution Y184F (Li et al., 2011). We also
found that Ala mutation of either of the closely located vicinal
disulphides (C186, C187) decreased the afﬁnity for epibatidine
by > 30-fold. This is consistent with the increased EC50 of ACh that
is seen when the equivalent residue is mutated in other nACh re-
ceptor subtypes such as a1 subunit-containing nACh receptors
(Blum et al., 2011; Karlin and Bartels, 1966). In a1 nicotinic subunits
the disulphide bond formed by these adjacent Cys is proposed to
distort loop C and enable key residues to interact with loop F on the
opposite side of the binding interface, and at a7 nACh receptors
they may have a similar role (Blum et al., 2011).
On the complementary face of the binding site, W53 in loop D
also constitutes part of the aromatic box. We show that binding is
undetectable following Cys mutation of this residue at a7 nACh
receptors. In the AChBP crystal structure 3SQ6, W53 stabilises
W145 via edge-to-face interactions rather than making a direct
contact with epibatidine. Such an interaction is consistent with the
relatively small afﬁnity change (4-fold) for epibatidine when a
conservative aromatic W53F substitution is made and the larger
reduction (17-fold; from 0.34 mM to 5.8 mM) in the EC50 of epi-
batidinewhen the same residue is substituted by Ala (Li et al., 2011;
Van Arnam et al., 2013). In Aplysia AChBP (2BYQ) the same position
is a Tyr, and mutating this to Trp increase the afﬁnity of epibatidine
to a value more closely resembling a7 nACh receptors, indicating
that stabilisation of W145 may be more optimal with a larger ar-
omatic residue at position 53 (Hansen et al., 2005). Q55C is closely
located to W53, but the afﬁnity of epibatidine at the mutant re-
ceptor was unaltered when compared to wild type a7 nACh re-
ceptors. A similar absence of major effects following Cys
substitution of this residue have been reported in functional studies
of other agonists at a7 nACh receptors (Papke et al., 2011). Based on
these ﬁndings and the orientation of epibatidine in both of the co-
crystal structures it is unlikely that this residue makes substantial
contact with the ligand or affects gating. Also present in the com-
plementary binding interface, the AChBP crystal structures indicate
that the equivalent of loop E residues N104, L106, Q114 and L116
stabilise epibatidine via Van der Waals interactions with its chlor-
opyridine ring (Hansen et al., 2005; Li et al., 2011). We found that
the binding afﬁnity was unaltered by Cys substitution of L106 and
L116, possibly owing to the similar size and hydrophobicity of
leucine and Cys (Nagano et al., 1999). For L106 our results are the
same as those for L106A which does not affect the EC50 of epi-
batidine, ACh or varenicline (Van Arnam et al., 2013). In contrast,
our results for L116 appear to conﬂict with reports that showed Ala
mutation causes a 9-fold change in the EC50 of epibatidine, and that
the equivalent residue makes an important hydrogen-bond with
agonists in a4b2 nACh receptors (Blum et al., 2013; Van Arnam
et al., 2013). However, when the backbone of L116 was probed by
unnatural amino acid mutagenesis to determine if hydrogen-
bonding was important at a7 nACh receptors, there were only
minor effects on the binding of epibatidine, ACh and varenicline,
suggesting that this residue does not have the same role as that
found in a4b2 nACh receptors (Van Arnam et al., 2013). Further-
more, a lack of effects on activation by other agonists has been
previously seen following Cys substitution at L116, and changes
may be dependent upon the ligand and the residue substitution
(Amiri et al., 2008; Papke et al., 2011). For Q114 a halogen-bonding
interaction between the backbone carbonyl and the pyridine
chlorine of epibatidine is seen in AChBP (Li et al., 2011). Consistent
with this, removal of the side chain of Q114 by substitution to Ala
has little effect on the EC50 of epibatidine and other a7 nACh
Fig. 5. A comparison of the orientations of epibatidine (yellow, displayed as a ball-and-stick model) in the different binding sites of 2BYQ and 3SQ6, showing the accessibility of
different regions of the ligand. A, B. The surface of the protein has been hidden in panel A to show the location of epibatidine in the binding site, relative to binding loops B and C.
The orientation shown in panel B is the same as that in panel A, but with the protein surface visible. This is the only orientation found in all ten binding sites from 3SQ6 and the C-40
position is most accessible. C. Accessibility of the C-50 position is seen in 2BYQ where it is found in four of the ﬁve binding sites. D. In 2BYQ, one of the binding poses (chains B & A)
also exposes the N-10 position. The atom numbering used in this ﬁgure can be seen in Fig. 1. Potential hydrogen bonds are indicated by yellow dashes. (For interpretation of the
references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
A.J. Thompson et al. / Neuropharmacology 116 (2017) 421e428 427receptor agonists (Van Arnam et al., 2013). We did not probe main
chain interactions, but our ﬁndings suggest that Cys mutation may
have additional effects. For example, as Q114C increased the afﬁnity
for epibatidine by 5-fold, we speculate that this could reﬂect the
formation of an attractive non-covalent interaction between the
sulfhydryl group and the chlorine atom. Elsewhere in AChBP mu-
tation of residues in loop C is similarly reported to increase the
afﬁnity of ACh and it was also speculated that this might reﬂect
changes in electrostatic interactions (Li et al., 2011). In loop F,
neither D160C nor S162C mutations had any effect on the afﬁnity of
epibatidine, nor indeed are there any previous reports of these
residues mediating ligand interactions or functional effects. In
other studies, mutation of the closely located residue G167 also had
no effect on the function of epibatidine when mutated to a range of
other amino acids, and I161C and G167C had no effect on several
other a7 nACh receptor agonists, further indicating that this region
may not have a major role in binding (Matsuda et al., 2000; Papke
et al., 2011).
High-afﬁnity epibatidine binding has also been reported at 5-
HT3 receptors, similar to the binding of ACh, nicotine, tropisetron
and D-tubocurarine at the two receptor types (ChavezNoriega et al.,
1997; Drisdel et al., 2008; Thompson et al., 2014). In light of this we
also measured binding at the 5-HT3 receptor to establish whether
epibatidine could have utility for studying this other member of the
Cys-loop receptor family. However, saturable binding with [3H]epibatidine was not detected at either human or mouse 5-HT3 re-
ceptors at a concentration of up to 25 nM. This result was conﬁrmed
when competition of unlabelled epibatidine with the 5-HT3 re-
ceptor antagonist [3H]tropisetron yielded a pKi of 5.60 ± 0.02
(Ki ¼ 2.51 mM, n ¼ 3) for human and a pKi of 4.91 ± 0.12
(Ki ¼ 12.3 mM, n ¼ 4) for mouse, but contrasts with a report from
Drisdel et al. (2008) who found a nanomolar afﬁnity for epibatidine
at 5-HT3 receptors. It is unclear why there is a 100-fold difference
between our results, but the larger value we measured precludes
the possibility of using this ligand as precursor for developing novel
molecular probes for studying 5-HT3 receptors. In contrast, epi-
batidine may provide an opportunity for developing a7 nACh re-
ceptor probes, but previous efforts to couple ﬂuorophores at the C-
50 position (see Fig. 1 for atom numbering) caused a dramatic
reduction in afﬁnity (at worst, from nM to mM) and made the
resultant ﬂuorescent derivatives unsuitable for ﬂuorescence-based
experiments (Grandl et al., 2007). However, further analysis of
3SQ6 suggests that the C-40 position is more accessible than the C-
50 position. Indeed, all ten of the binding orientations in 3SQ6
(Fig. 5B) expose the C-40 position, while orientations in 2BYQ show
that either the C-50 is more accessible or that the pyridine ring is
ﬂipped by 180 which makes the C-20 most accessible (Fig. 5C and
D). The ﬁnding that C-50 substituted epibatidine derivatives still
bind within the tightly conﬁned space of the ligand binding site
shows that conjugation at this location does not prevent binding,
A.J. Thompson et al. / Neuropharmacology 116 (2017) 421e428428but the modiﬁcation is not optimal. Our ﬁnding that the orienta-
tions of epibatidine in the AChBP co-crystal structures are broadly
correct, and that 3SQ6 shows improved accessibility at the C-40
position, suggests that there may still be opportunities to develop
epibatidine-based probes with higher afﬁnities for the a7 nACh
receptor. In our previous work the development of similar probes
for targeting 5-HT3 receptors has enabled quantitative ﬂuorescent
measurements, receptor localisation and photo cross-linking to be
performed, and shows the value of pursing their synthesis (Lochner
and Thompson, 2015; Jack et al., 2014).
To visualise ligand-receptor interactions homologous proteins
are often used as substitutes for the native receptor, and AChBP is a
popular substitute for all Cys-loop receptors despite often quite
distinct pharmacologies for the same ligands at different receptors.
Here we speciﬁcally examined another of the structures, to deter-
minewhether changes in the afﬁnity of epibatidine caused by point
mutations in the a7 nACh receptor are consistent with residues
identiﬁed in epibatidine-bound AChBP crystals. The results pre-
sented here suggest that the orientations of epibatidine in the
AChBP crystal structures are a reasonable approximation of its
orientation at a7 nACh receptors. It is also striking how similarly
epibatidine binds in the two crystal structures despite the only
31.8% sequence identity between 2BYQ and 3SQ6. This similarity in
ligand orientation extends to the in silico docking presented here
and perhaps reﬂects the high conservation of major aromatic res-
idues that constitute the binding site (in 3SQ6 and the a7 nACh
receptor these residues are identical) and the tight pocket imposed
by the agonist-bound conformation. Furthermore, while the
accessibility of locations on the pyridine ring of epibatidine still
needs to be clariﬁed in more detail, we can now be more conﬁdent
of the crystal structures and use them as models for our ongoing
efforts to attach ﬂuorescent moieties to this ligand in order to
develop speciﬁc high-afﬁnity molecular probes for studying the a7
nACh receptor subtype. The use of cysteine mutants could also
provide a stimulus for probing ligand interactions by chemical
modiﬁcation (e.g. by methanethiosulfonate (MTS) reagents) of the
thiol side chains.
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